Risk-Adapted Targeted Therapy for Untreated MZL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a personalized treatment plan for people with newly diagnosed marginal zone lymphoma (MZL). The treatment is based on a risk score and aims to be more targeted than standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lymphoma called marginal zone lymphoma (MZL), confirmed by a biopsy.
- You must be 18 years or older.
- You must need treatment for your lymphoma. This might be because it's growing, causing symptoms, or has come back after local treatment like surgery or radiation.
- You should be in reasonably good health, with a performance status score of 0-2 (meaning you can care for yourself and are up and about more than half of the day).
- You cannot have had prior chemotherapy, immunotherapy, or targeted drugs for your lymphoma. Prior local treatment (surgery, radiation) is okay.
- You cannot have serious health problems like uncontrolled heart disease, active infections (including hepatitis B or C, HIV), or a history of another cancer in the last 3 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, orelabrutinib and rituximab, as the first systemic treatment for marginal zone lymphoma. If you have not yet had chemotherapy for your lymphoma and meet certain health criteria, you may be able to join.
This trial tests an oral medication called orelabrutinib as a follow-up treatment after initial therapy for marginal zone lymphoma that hasn't been treated yet. The goal is to see if it helps keep the lymphoma from coming back.
This trial tests a combination of three drugs (orelabrutinib, zebetuzumab, and lenalidomide) for people newly diagnosed with a type of lymphoma called marginal zone lymphoma (MZL). If you qualify, you may receive this treatment to help control the disease.
This trial tests a combination of targeted drugs for people with a type of lymphoma called marginal zone lymphoma (MZL) that has not been treated before. The drugs attack cancer cells in different ways, and the treatment plan may adjust based on how you respond.
This trial tests a new targeted drug (orelabrutinib) with or without another drug that targets CD20 (a protein on some immune cells) for people with untreated marginal zone lymphoma. It aims to see if this combination works better than other treatments and may be an option for those who cannot have radiation.
This trial tests a combination of three drugs (zanubrutinib, rituximab, and lenalidomide) as a first treatment for people with advanced marginal zone lymphoma. The goal is to see if this combination can help control the cancer without the need for chemotherapy.
Hear when a new Marginal Zone Lymphoma(MZL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.